{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:06:53Z","timestamp":1791821213698,"version":"4.3.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10787-025-01865-0","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T17:45:59Z","timestamp":1753465559000},"page":"4275-4290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Psoriatic arthritis in transition: cytokine signaling, immune dysregulation, and therapeutic innovation"],"prefix":"10.1007","volume":"33","author":[{"given":"Sanjana","family":"Sahu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9013-9839","authenticated-orcid":false,"given":"Parag","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohitas","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep Kumar","family":"Samal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trilochan","family":"Satapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ajazuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"1865_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/OARRR.S347797","volume":"14","author":"R Aljohani","year":"2022","unstructured":"Aljohani R (2022) Metabolic syndrome and its components in psoriatic arthritis. Open Access Rheumatol Res Rev 14:7\u201316. https:\/\/doi.org\/10.2147\/OARRR.S347797","journal-title":"Open Access Rheumatol Res Rev"},{"issue":"2","key":"1865_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/S12016-012-8304-4","volume":"44","author":"A Anandarajah","year":"2013","unstructured":"Anandarajah A (2013) Imaging in psoriatic arthritis. Clin Rev Allergy Immunol 44(2):157\u2013165. https:\/\/doi.org\/10.1007\/S12016-012-8304-4","journal-title":"Clin Rev Allergy Immunol"},{"key":"1865_CR3","doi-asserted-by":"publisher","unstructured":"Ashraf, F., and Kutty, S. M. (2025) Bimekizumab: A novel FDA approved dual IL-17 A\/F inhibitor for moderate to severe psoriasis. Indian J Dermatol Venereol Leprol. 91(2): 226\u2013230. https:\/\/doi.org\/10.25259\/IJDVL_867_2024","DOI":"10.25259\/IJDVL_867_2024"},{"issue":"5","key":"1865_CR4","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.3390\/IJMS24054901","volume":"24","author":"AB Azuaga","year":"2023","unstructured":"Azuaga AB, Ram\u00edrez J, Ca\u00f1ete JD (2023) Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci 24(5):4901. https:\/\/doi.org\/10.3390\/IJMS24054901","journal-title":"Int J Mol Sci"},{"key":"1865_CR5","doi-asserted-by":"publisher","first-page":"113181","DOI":"10.1016\/j.biopha.2022.113181","volume":"152","author":"C Baggio","year":"2022","unstructured":"Baggio C, Boscaro C, Oliviero F, Trevisi L, Ramaschi G, Ramonda R, Bolego C, Cignarella A (2022) Gender differences and pharmacological regulation of angiogenesis induced by synovial fluids in inflammatory arthritis. Biomed Pharmacother 152:113181. https:\/\/doi.org\/10.1016\/j.biopha.2022.113181","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1865_CR6","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/ART.38995","volume":"67","author":"J Belasco","year":"2015","unstructured":"Belasco J, Louie JS, Gulati N, Wei N, Nograles K, Fuentes-Duculan J, Mitsui H, Su\u00e1rez-Fari\u00f1as M, Krueger JG (2015) Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthrit Rheumatol 67(4):934\u2013944. https:\/\/doi.org\/10.1002\/ART.38995","journal-title":"Arthrit Rheumatol"},{"issue":"11","key":"1865_CR7","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3390\/BIOMEDICINES9111511","volume":"9","author":"A Campanati","year":"2021","unstructured":"Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A (2021) Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches. Biomedicines. 9(11):1511. https:\/\/doi.org\/10.3390\/BIOMEDICINES9111511","journal-title":"Biomedicines."},{"key":"1865_CR8","doi-asserted-by":"publisher","first-page":"662047","DOI":"10.3389\/FMOLB.2021.662047","volume":"8","author":"AL Carvalho","year":"2021","unstructured":"Carvalho AL, Hedrich CM (2021) The molecular pathophysiology of psoriatic arthritis-the complex interplay between genetic predisposition, epigenetics factors, and the microbiome. Front Mol Biosci 8:662047. https:\/\/doi.org\/10.3389\/FMOLB.2021.662047","journal-title":"Front Mol Biosci"},{"issue":"3","key":"1865_CR9","doi-asserted-by":"publisher","first-page":"J314","DOI":"10.1016\/J.JAUT.2009.12.001","volume":"34","author":"V Chandran","year":"2010","unstructured":"Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34(3):J314\u2013J321. https:\/\/doi.org\/10.1016\/J.JAUT.2009.12.001","journal-title":"J Autoimmun"},{"key":"1865_CR10","doi-asserted-by":"publisher","first-page":"737256","DOI":"10.3389\/FMED.2021.737256","volume":"8","author":"AYT Chia","year":"2021","unstructured":"Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY (2021) Managing psoriatic arthritis with inflammatory bowel disease and\/or uveitis. Front Med 8:737256. https:\/\/doi.org\/10.3389\/FMED.2021.737256","journal-title":"Front Med"},{"issue":"2","key":"1865_CR11","doi-asserted-by":"publisher","first-page":"e001240","DOI":"10.1136\/RMDOPEN-2020-001240","volume":"6","author":"PG Conaghan","year":"2020","unstructured":"Conaghan PG, Alten R, Deodhar A, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl SM, Strand V (2020) Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study. RMD Open 6(2):e001240. https:\/\/doi.org\/10.1136\/RMDOPEN-2020-001240","journal-title":"RMD Open"},{"issue":"2","key":"1865_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/S40744-020-00206-7","volume":"7","author":"G Dal Bello","year":"2020","unstructured":"Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G (2020) Psoriatic arthritis and diabetes mellitus: a narrative review. Rheumatol Ther 7(2):271\u2013285. https:\/\/doi.org\/10.1007\/S40744-020-00206-7","journal-title":"Rheumatol Ther"},{"issue":"12","key":"1865_CR13","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/JDV.15177","volume":"32","author":"E Dauden","year":"2018","unstructured":"Dauden E, Blasco AJ, Bonanad C, Botella R, Carrascosa JM, Gonz\u00e1lez-Parra E, Jodar E, Joven B, L\u00e1zaro P, Olveira A, Quintero J, Rivera R (2018) Position statement for the management of comorbidities in psoriasis. J Euro Acad Dermatol Venereol 32(12):2058\u20132073. https:\/\/doi.org\/10.1111\/JDV.15177","journal-title":"J Euro Acad Dermatol Venereol"},{"issue":"6","key":"1865_CR14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/ANNRHEUMDIS-2015-207963","volume":"75","author":"CJ Edwards","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P (2016) Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 75(6):1065\u20131073. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2015-207963","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1865_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/2040622312459673","volume":"3","author":"LR Espinoza","year":"2012","unstructured":"Espinoza LR, Cuchacovich R, Perez Alamino R, Garcia Valladares I (2012) Steps in the management of psoriatic arthritis: a guide for clinicians. Ther Adv Chronic Dis 3(6):259\u2013269. https:\/\/doi.org\/10.1177\/2040622312459673","journal-title":"Ther Adv Chronic Dis"},{"key":"1865_CR16","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3389\/FIMMU.2019.01232","volume":"10","author":"MT Fiorillo","year":"2019","unstructured":"Fiorillo MT, Haroon N, Ciccia F, Breban M (2019) Editorial: ankylosing spondylitis and related immune-mediated disorders. Front Immunol 10:1232. https:\/\/doi.org\/10.3389\/FIMMU.2019.01232","journal-title":"Front Immunol"},{"issue":"4","key":"1865_CR17","doi-asserted-by":"publisher","first-page":"573.e1","DOI":"10.1016\/J.JAAD.2005.03.046","volume":"53","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T (2005) Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53(4):573.e1-573.e13. https:\/\/doi.org\/10.1016\/J.JAAD.2005.03.046","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1865_CR18","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/J.CLINTHERA.2024.05.005","volume":"46","author":"R Gopalarathinam","year":"2024","unstructured":"Gopalarathinam R, Sankar R, Zhao SS (2024) Role of anti-inflammatory diet and fecal microbiota transplant in psoriatic arthritis. Clin Ther 46(7):588\u2013596. https:\/\/doi.org\/10.1016\/J.CLINTHERA.2024.05.005","journal-title":"Clin Ther"},{"issue":"2","key":"1865_CR19","doi-asserted-by":"publisher","first-page":"e000293","DOI":"10.1136\/RMDOPEN-2016-000293","volume":"2","author":"N Haque","year":"2016","unstructured":"Haque N, Lories RJ, de Vlam K (2016) Orthopaedic interventions in patients with psoriatic arthritis: a descriptive report from the SPAR cohort. RMD Open 2(2):e000293. https:\/\/doi.org\/10.1136\/RMDOPEN-2016-000293","journal-title":"RMD Open"},{"issue":"1","key":"1865_CR20","doi-asserted-by":"publisher","first-page":"e001223","DOI":"10.1136\/RMDOPEN-2020-001223","volume":"6","author":"G Haugeberg","year":"2020","unstructured":"Haugeberg G, Michelsen B, Kavanaugh A (2020) Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: a cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open 6(1):e001223. https:\/\/doi.org\/10.1136\/RMDOPEN-2020-001223","journal-title":"RMD Open"},{"issue":"3","key":"1865_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/J.SEMARTHRIT.2017.05.010","volume":"47","author":"ME Husni","year":"2017","unstructured":"Husni ME, Merola JF, Davin S (2017) The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 47(3):351\u2013360. https:\/\/doi.org\/10.1016\/J.SEMARTHRIT.2017.05.010","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1865_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/PHARMACEUTICS15020385","volume":"15","author":"H Iznardo","year":"2023","unstructured":"Iznardo H, Ro\u00e9 E, Serra-Baldrich E, Puig L (2023) Efficacy and safety of JAK1 inhibitor abrocitinib in atopic dermatitis. Pharmaceutics 15(2):385. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15020385","journal-title":"Pharmaceutics"},{"issue":"2","key":"1865_CR23","doi-asserted-by":"publisher","first-page":"101692","DOI":"10.1016\/j.berh.2021.101692","volume":"35","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya P, Chakradhar R, Ogdie A (2021) The epidemiology of psoriatic arthritis: a literature review. Best Prac Res Clin Rheumatol. 35(2):101692. https:\/\/doi.org\/10.1016\/j.berh.2021.101692","journal-title":"Best Prac Res Clin Rheumatol."},{"issue":"2","key":"1865_CR24","doi-asserted-by":"publisher","first-page":"101670","DOI":"10.1016\/J.BERH.2021.101670","volume":"35","author":"M Kishimoto","year":"2021","unstructured":"Kishimoto M, Deshpande GA, Fukuoka K, Kawakami T, Ikegaya N, Kawashima S, Komagata Y, Kaname S (2021) Clinical features of psoriatic arthritis. Best Pract Res Clin Rheumatol 35(2):101670. https:\/\/doi.org\/10.1016\/J.BERH.2021.101670","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"1865_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.5114\/ADA.2019.83983","volume":"37","author":"EH Klujszo","year":"2020","unstructured":"Klujszo EH, Parcheta P, Witkowska AB, Krecisz B (2020) Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications. Postepy Dermatol Alergol 37(4):468\u2013474. https:\/\/doi.org\/10.5114\/ADA.2019.83983","journal-title":"Postepy Dermatol Alergol"},{"issue":"1","key":"1865_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-61981-5","volume":"10","author":"Q Li","year":"2020","unstructured":"Li Q, Chandran V, Tsoi L, O\u2019Rielly D, Nair RP, Gladman D, Elder JT, Rahman P (2020) Quantifying differences in heritability among psoriatic arthritis (PsA), cutaneous psoriasis (PsC) and psoriasis vulgaris (PsV). Sci Rep 10(1):1\u20136. https:\/\/doi.org\/10.1038\/s41598-020-61981-5","journal-title":"Sci Rep"},{"issue":"2","key":"1865_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/S40744-020-00207-6","volume":"7","author":"AJ Mathew","year":"2020","unstructured":"Mathew AJ, Chandran V (2020) Depression in psoriatic arthritis: dimensional aspects and link with systemic inflammation. Rheumatol Ther 7(2):287\u2013300. https:\/\/doi.org\/10.1007\/S40744-020-00207-6","journal-title":"Rheumatol Ther"},{"issue":"4","key":"1865_CR28","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","volume":"2","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, Conaghan PG, Kirkham B, Navarra S, Belsare AD, Delicha EM, Pricop L (2020) Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. Lancet Rheumatol 2(4):e227\u2013e235. https:\/\/doi.org\/10.1016\/S2665-9913(20)30036-9","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"1865_CR29","doi-asserted-by":"publisher","first-page":"e001838","DOI":"10.1136\/RMDOPEN-2021-001838","volume":"7","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Kato K, Magrey M, Merola JF, Kishimoto M, Pacheco-Tena C, Haaland D, Chen L, Duan Y, Zueger P, Liu J, Lippe R, Pangan AL, Behrens F (2021) Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open 7(3):e001838. https:\/\/doi.org\/10.1136\/RMDOPEN-2021-001838","journal-title":"RMD Open"},{"issue":"3","key":"1865_CR30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ART.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL, Jiang Y, Sheng S, Shawi M, Chakravarty SD, van der Heijde D, Mease PJ (2022) Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of Interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with act. Arthrit Rheumatol 74(3):475. https:\/\/doi.org\/10.1002\/ART.42010","journal-title":"Arthrit Rheumatol"},{"key":"1865_CR500","doi-asserted-by":"publisher","unstructured":"McTaggart T, Lim JX, Smith KJ, Heaney B, McDonald D, Hulme G, Hussain R, Coxhead J, Degnan AE, Isaacs J, Pratt A, Amarnath S (2025) Deep phenotyping of T regulatory cells in psoriatic arthritis highlights targetable mechanisms of disease. J Biol Chem 301(1):108059. https:\/\/doi.org\/10.1016\/j.jbc.2024.108059.","DOI":"10.1016\/j.jbc.2024.108059"},{"issue":"1","key":"1865_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/ANNRHEUMDIS-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Van Der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of t. Ann Rheum Dis 76(1):79\u201387. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2016-209709","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1865_CR32","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/J.SEMARTHRIT.2018.05.010","volume":"48","author":"P Mease","year":"2018","unstructured":"Mease P, Strand V, Gladman D (2018) Functional impairment measurement in psoriatic arthritis: importance and challenges. Semin Arthritis Rheum 48(3):436\u2013448. https:\/\/doi.org\/10.1016\/J.SEMARTHRIT.2018.05.010","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"1865_CR33","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S2665-9913(21)00010-2","volume":"3","author":"P Nash","year":"2021","unstructured":"Nash P, Coates LC, Fleishaker D, Kivitz AJ, Mease PJ, Gladman DD, FitzGerald O, Wang C, Wu J, Hsu MA, Menon S, Fallon L, Kanik KS (2021) Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL balance long-term extension study. Lancet Rheumatol 3(4):e270\u2013e283. https:\/\/doi.org\/10.1016\/S2665-9913(21)00010-2","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"1865_CR34","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/ANNRHEUMDIS-2021-220249","volume":"80","author":"E Nikiphorou","year":"2021","unstructured":"Nikiphorou E, Santos EJF, Marques A, B\u00f6hm P, Bijlsma JWJ, Daien CI, Esbensen BA, Ferreira RJO, Fragoulis GE, Holmes P, McBain H, Metsios GS, Moe RH, Stamm TA, de Thurah A, Zabalan C, Carmona L, Bosworth A (2021) 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Ann Rheum Dis 80(10):1278\u20131285. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2021-220249","journal-title":"Ann Rheum Dis"},{"key":"1865_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3899\/JRHEUM.190119","volume":"95","author":"DD O\u2019Rielly","year":"2019","unstructured":"O\u2019Rielly DD, Jani M, Rahman P, Elder JT (2019) The genetics of psoriasis and psoriatic arthritis. J Rheumatol Suppl 95:46\u201350. https:\/\/doi.org\/10.3899\/JRHEUM.190119","journal-title":"J Rheumatol Suppl"},{"issue":"10","key":"1865_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/S11926-015-0540-1","volume":"17","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Gelfand JM (2015) Clinical risk factors for the development of psoriatic artrhritis among patients with psoriasis: a review of available evidence. Curr Rheumatol Rep 17(10):64. https:\/\/doi.org\/10.1007\/S11926-015-0540-1","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"1865_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/J.RDC.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 41(4):545\u2013568. https:\/\/doi.org\/10.1016\/J.RDC.2015.07.001","journal-title":"Rheum Dis Clin North Am"},{"key":"1865_CR38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ACR.24242","volume":"72","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Coates LC, Mease P (2020) Measuring outcomes in psoriatic arthritis. Arthritis Care Res 72:82\u2013109. https:\/\/doi.org\/10.1002\/ACR.24242","journal-title":"Arthritis Care Res"},{"issue":"2","key":"1865_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/J.RDC.2016.01.002","volume":"42","author":"AM Orbai","year":"2016","unstructured":"Orbai AM, Ogdie A (2016) Patient-reported outcomes in psoriatic arthritis. Rheum Dis Clin North Am 42(2):265\u2013283. https:\/\/doi.org\/10.1016\/J.RDC.2016.01.002","journal-title":"Rheum Dis Clin North Am"},{"issue":"7","key":"1865_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1358\/DOT.2018.54.7.2866117","volume":"54","author":"DM Paton","year":"2018","unstructured":"Paton DM (2018) Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis. Drugs Today 54(7):433\u2013444. https:\/\/doi.org\/10.1358\/DOT.2018.54.7.2866117","journal-title":"Drugs Today"},{"key":"1865_CR41","doi-asserted-by":"publisher","first-page":"108397","DOI":"10.1016\/J.CLIM.2020.108397","volume":"214","author":"LM Perez-Chada","year":"2020","unstructured":"Perez-Chada LM, Merola JF (2020) Comorbidities associated with psoriatic arthritis: review and update. Clin Immunol 214:108397. https:\/\/doi.org\/10.1016\/J.CLIM.2020.108397","journal-title":"Clin Immunol"},{"issue":"2","key":"1865_CR42","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/S40744-021-00298-9","volume":"8","author":"FM Perrotta","year":"2021","unstructured":"Perrotta FM, Scriffignano S, Benfaremo D, Ronga M, Luchetti MM, Lubrano E (2021) New insights in physical therapy and rehabilitation in psoriatic arthritis: a review. Rheumatol Ther 8(2):639\u2013649. https:\/\/doi.org\/10.1007\/S40744-021-00298-9","journal-title":"Rheumatol Ther"},{"issue":"4","key":"1865_CR43","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/J.RDC.2015.07.007","volume":"41","author":"RP Poggenborg","year":"2015","unstructured":"Poggenborg RP, \u00d8stergaard M, Terslev L (2015) Imaging in psoriatic arthritis. Rheum Dis Clin North Am 41(4):593\u2013613. https:\/\/doi.org\/10.1016\/J.RDC.2015.07.007","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"1865_CR44","doi-asserted-by":"publisher","first-page":"e001457","DOI":"10.1136\/RMDOPEN-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke WH, Soriano ER, Hsia EC, Kollmeier AP, Chakravarty SD, Zazzetti F, Subramanian RA, Xu XL, Zuraw QC, Sheng S, Jiang Y, Agarwal P, Zhou B, Zhuang Y, Shawi M, Karyekar CS, Deodhar A (2021) Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na\u00efve or TNF\u03b1 inhibitor-experienced. RMD Open 7(1):e001457. https:\/\/doi.org\/10.1136\/RMDOPEN-2020-001457","journal-title":"RMD Open"},{"issue":"1","key":"1865_CR45","doi-asserted-by":"publisher","first-page":"e001117","DOI":"10.1136\/RMDOPEN-2019-001117","volume":"6","author":"A Ruyssen-Witrand","year":"2020","unstructured":"Ruyssen-Witrand A, Perry R, Watkins C, Braileanu G, Kumar G, Kiri S, Nott D, Liu-Leage S, Hartz S, Sapin C (2020) Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open 6(1):e001117. https:\/\/doi.org\/10.1136\/RMDOPEN-2019-001117","journal-title":"RMD Open"},{"key":"1865_CR46","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/J.RCREU.2022.11.001","volume":"30","author":"DC Sandoval","year":"2023","unstructured":"Sandoval DC, Fern\u00e1ndez-\u00c1vila DG (2023) Assessment tools in psoriatic arthritis: a review. Rev Colomb Reumatol 30:S75\u2013S86. https:\/\/doi.org\/10.1016\/J.RCREU.2022.11.001","journal-title":"Rev Colomb Reumatol"},{"issue":"1","key":"1865_CR47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/S41927-022-00287-7","volume":"6","author":"S Sarabia","year":"2022","unstructured":"Sarabia S, Ranjith B, Koppikar S, Wijeratne DT (2022) Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. BMC Rheumatol 6(1):71. https:\/\/doi.org\/10.1186\/S41927-022-00287-7","journal-title":"BMC Rheumatol"},{"issue":"1","key":"1865_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/1744666X.2019.1544892","volume":"15","author":"L Serhal","year":"2019","unstructured":"Serhal L, Edwards CJ (2019) Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 15(1):13\u201325. https:\/\/doi.org\/10.1080\/1744666X.2019.1544892","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"1865_CR49","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1136\/ARD.2005.039826","volume":"65","author":"F Siannis","year":"2005","unstructured":"Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DDD (2005) Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis 65(4):478. https:\/\/doi.org\/10.1136\/ARD.2005.039826","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1865_CR50","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5114\/REUM.2017.68912","volume":"55","author":"P Sobolewski","year":"2017","unstructured":"Sobolewski P, Walecka I, Dopytalska K (2017) Nail involvement in psoriatic arthritis. Reumatologia 55(3):131\u2013135. https:\/\/doi.org\/10.5114\/REUM.2017.68912","journal-title":"Reumatologia"},{"issue":"2","key":"1865_CR51","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1124\/JPET.122.001512","volume":"387","author":"B Steere","year":"2023","unstructured":"Steere B, Beidler C, Martin A, Bright S, Kikly K, Benschop RJ (2023) Generation and characterization of Mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23. J Pharmacol Exp Ther 387(2):180\u2013187. https:\/\/doi.org\/10.1124\/JPET.122.001512","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1865_CR52","doi-asserted-by":"publisher","first-page":"101694","DOI":"10.1016\/j.berh.2021.101694","volume":"35","author":"C Stober","year":"2021","unstructured":"Stober C (2021) Pathogenesis of psoriatic arthritis. Best Pract Res Clin Rheumatol 35(2):101694. https:\/\/doi.org\/10.1016\/j.berh.2021.101694","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"1865_CR53","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.3390\/IJMS24076384","volume":"24","author":"S Sundanum","year":"2023","unstructured":"Sundanum S, Orr C, Veale D (2023) Targeted therapies in psoriatic arthritis-an update. Int J Mol Sci 24(7):6384. https:\/\/doi.org\/10.3390\/IJMS24076384","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1865_CR54","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/ART.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673. https:\/\/doi.org\/10.1002\/ART.21972","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1865_CR55","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/10600280231153863","volume":"58","author":"TM Truong","year":"2024","unstructured":"Truong TM, Pathak GN, Singal A, Taranto V, Rao BK (2024) Deucravacitinib: the first FDA-approved oral TYK2 inhibitor for moderate to severe plaque psoriasis. Ann Pharmacother 58(4):416\u2013427. https:\/\/doi.org\/10.1177\/10600280231153863","journal-title":"Ann Pharmacother"},{"issue":"5","key":"1865_CR56","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ARD.2003.013052","volume":"63","author":"LBA Van De Putte","year":"2004","unstructured":"Van De Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, Van Riel PLCM, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63(5):508\u2013516. https:\/\/doi.org\/10.1136\/ARD.2003.013052","journal-title":"Ann Rheum Dis"},{"issue":"10136","key":"1865_CR57","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","volume":"391","author":"F Van den Bosch","year":"2018","unstructured":"Van den Bosch F, Coates L (2018) Clinical management of psoriatic arthritis. Lancet (London, England) 391(10136):2285\u20132294. https:\/\/doi.org\/10.1016\/S0140-6736(18)30949-8","journal-title":"Lancet (London, England)"},{"issue":"8","key":"1865_CR58","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1111\/CED.15174","volume":"47","author":"D Wi","year":"2022","unstructured":"Wi D, Wilson A, Satg\u00e9 F, Murrell DF (2022) Psoriasis and osteoporosis: a literature review. Clin Exp Dermatol 47(8):1438. https:\/\/doi.org\/10.1111\/CED.15174","journal-title":"Clin Exp Dermatol"},{"key":"1865_CR59","doi-asserted-by":"publisher","first-page":"1054539","DOI":"10.3389\/FIMMU.2022.1054539","volume":"13","author":"T Wirth","year":"2022","unstructured":"Wirth T, Balandraud N, Boyer L, Lafforgue P, Pham T (2022) Biomarkers in psoriatic arthritis: a meta-analysis and systematic review. Front Immunol 13:1054539. https:\/\/doi.org\/10.3389\/FIMMU.2022.1054539","journal-title":"Front Immunol"},{"issue":"5","key":"1865_CR60","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/MEDICINA60050815","volume":"60","author":"M Zalesak","year":"2024","unstructured":"Zalesak M, Danisovic L, Harsanyi S (2024) Psoriasis and psoriatic arthritis-associated genes, cytokines, and human leukocyte antigens. Medicina (Kaunas) 60(5):815. https:\/\/doi.org\/10.3390\/MEDICINA60050815","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"1865_CR61","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/J.CLINDERMATOL.2018.04.011","volume":"36","author":"A Zhang","year":"2018","unstructured":"Zhang A, Kurtzman DJB, Perez-Chada LM, Merola JF (2018) Psoriatic arthritis and the dermatologist: an approach to screening and clinical evaluation. Clin Dermatol 36(4):551\u2013560. https:\/\/doi.org\/10.1016\/J.CLINDERMATOL.2018.04.011","journal-title":"Clin Dermatol"},{"key":"1865_CR62","doi-asserted-by":"publisher","first-page":"714321","DOI":"10.1155\/2012\/714321","volume":"2012","author":"TY Zhu","year":"2012","unstructured":"Zhu TY, Li EK, Tam LS (2012) Cardiovascular risk in patients with psoriatic arthritis. Int J Rheumatol 2012:714321. https:\/\/doi.org\/10.1155\/2012\/714321","journal-title":"Int J Rheumatol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01865-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01865-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01865-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T16:37:29Z","timestamp":1756485449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01865-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01865-0","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}